<DOC>
	<DOCNO>NCT00005874</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness nitrocamptothecin treat patient locally advance metastatic soft tissue sarcoma .</brief_summary>
	<brief_title>Nitrocamptothecin Treating Patients With Soft Tissue Sarcomas</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy toxicity nitrocamptothecin patient locally advance metastatic gastrointestinal leiomyosarcoma soft tissue sarcoma . OUTLINE : Patients stratify disease ( gastrointestinal leiomyosarcoma v soft tissue sarcoma ) . Patients receive oral nitrocamptothecin daily day 1-5 . Treatment continue weekly absence disease progression unacceptable toxicity . Responding patient undergo surgery receive additional 4-6 course ( 4 weeks/course ) . PROJECTED ACCRUAL : A total 34-78 patient ( 17-39 per stratum ) accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally advanced metastatic inoperable soft tissue sarcoma Measurable evaluable disease irradiate Must receive , refuse , eligible doxorubicin/ifosfamide treatment Previously untreated gastrointestinal leiomyosarcoma allow PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 3 time normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No active coronary disease require therapy Pulmonary : No severe pulmonary insufficiency Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No prior malignancy past 3 year except nonmelanoma skin cancer carcinoma situ cervix No concurrent active infection No psychosis mental disability would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 7 day since prior biological therapy recover No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : At least 7 day since prior hormonal therapy recover Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>childhood leiomyosarcoma</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>